Team

The TVM Capital Life Science Venture team works as an integrated, transatlantic task force.

› navigate
TVM Capital Life Science Team

Dr. Hubert Birner

hubert-birner

Managing Partner (based in Montreal) Dr. Birner is responsible for TVM Capital Life Sciences’ overall investment strategy going forward and the fund operations in North America and Europe. Dr. Birner joined TVM Capital in 2000 as an investment manager. He is responsible for numerous active investments in Europe as well as the United States. He currently serves as Chairman of the Board of Argos Therapeutics Inc. (Durham, North Carolina) and is a member of the Board of Directors of Proteon Therapeutics, Inc (Kansas City, Missouri) and SpePharm Holding BV (Amsterdam, NL). Over many years, he was the Chairman/Vice Chairman of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany) which were acquired in 2008 by Bayer HealthCare AG and Shire Ltd. respectively.

Stefan Fischer

Stefan Fischer

General Partner Corporate Finance and Chief Financial Officer (based in Munich) Stefan Fischer joined TVM Capital in 2000 and is General Partner Corporate Finance at TVM Capital in Munich. He has been responsible for the corporate finance side of the investment activities of the life science team for many years and was actively involved in numerous IPOs and trade sales of TVM Capital portfolio companies. Stefan Fischer made major contributions to the fundraising of TVM Life Sciences Ventures VII and is now promoted to Chief Financial Officer of the firm. Mr. Fischer is the Chairman of the Supervisory Board of pritidenta GmbH (Leinfelden-Echterdingen, Germany), the Vice-Chairman of the Supervisory Board of Direvo IBT GmbH (Cologne, Germany) and serves as a board observer to Biovertis AG (Vienna, Austria). Mr. Fischer holds overall responsibility for the finance operations of our Munich and Montreal offices as well as for our life science venture capital funds..

Dr. Alexandra Goll

Dr. Alexandra Goll

General Partner (based in Munich)

Dr. Alexandra Goll, who joined TVM Capital in early 1998 has been responsible for more than 20 TVM Capital life science investments. She initiated TVM Capital’s lead investment in Actelion Ltd (Allschwil, Switzerland) and led the firm’s successful investments in Idenix Pharmaceuticals, Inc. sold to Novartis, and Pharmasset Inc. which was sold to Gilead Sciences – TVM Capital acted as a lead investor in both cases. She also initiated and managed the investment in EUSA Pharma Ltd., recently sold to Jazz Pharmaceuticals Inc.

Dr. Cynthia Lavoie

Cynthia Lavoie

General Partner (based in Montreal)

Dr. Lavoie is a General Partner with TVM Life Science Management Inc. She is located in Montreal and is responsible for the  investment strategy in Canada and the management of  portfolio companies in the US and Canada. Cynthia serves on the boards of Anchor Therapeutics and Kaneq Bioscience. She was previously with VG Partners, a large Canadian private equity firm, where her most recent role was as Partner and head of life sciences. She served on the boards of investee companies Aegera Therapeutics, Cytochroma, Interface Biologics, Trillium Therapeutics and Zelos Therapeutics, among others. During her tenure, Cynthia had a direct role in the sale of VisualSonics, an imaging company, to SonoSite Inc., and Targanta Therapeutics to The Medicines Company.

Dr. Luc Marengere

Dr. Luc Marengere

Managing Partner (based in Montreal)

Dr. Marengere oversees the establishment of the new Canadian operations and the North American investment strategy as well as deal sourcing and execution.

Dr. Marengere joins TVM Capital after more than 15 years of venture capital experience in Canada and the U.S. Most recently, Dr. Marengere was a Managing General Partner with VG Partners where he successfully launched and oversaw the operations and investments of the VG Advanced Life Sciences Fund (VG ALSF).

Dr. Peter Neubeck

Dr. Peter Neubeck

Venture Partner (based in Munich) Dr. Peter Neubeck is currently a Chief Business Officer at Aspireo Pharmaceuticals Ltd. As a venture partner at TVM Capital, he supports deal origination and the evaluation of new investments, as well as research and support for existing portfolio companies with an emphasis on clinical development stage to commercial stage investments, including virtual asset development type investments (‘Project-Focused-Companies’).

Dr. Axel Polack

Dr. Axel Polack

General Partner (based in Munich)

Marc Rivière, MD

Marc Riviere

General Partner (based in Montréal)Marc Rivière, General Partner, joined the Montréal-based Managing Partners, Dr. Hubert Birner and Dr. Luc Marengère as well as General Partner Dr. Cynthia Lavoie in 2013. Marc Rivière has been a Québec resident for 20 years after ten years of clinical, health economics and public health practice in Europe and the Middle East. He brings a broad product development experience backed by many years in leadership roles with service providers and with entrepreneurially led companies such as Axcan Pharma and Quintiles Inc. At TVM Life Science Management Inc., he focuses on evaluation of deal opportunities and investment management for therapeutics. He also works closely with the firm’s strategic partner Eli Lilly & Co. and its drug development division Chorus. Marc is a board certified MD  (Université Paul Sabatier, Toulouse, France) trained in Family Medicine and Tropical Diseases (Université Victor Segalen, Bordeaux, France).

Dr. Helmut M. Schühsler

Dr. Helmut M. Schühsler

Chairman & Managing Partner (based in Munich and Dubai)Dr. Helmut M. Schühsler serves as Chairman and Managing Partner of the TVM Life Science Venture Capital Practice with offices in Munich and Montreal and as Chairman and Chief Executive Officer of TVM Capital MENA Ltd., Dubai, UAE.

Since joining TVM Capital in 1990, Dr. Schühsler has been the deal maker on more than 20 direct investments in life science companies in Europe and the U.S. In total he has overseen more than 80 investments in the health market and has built the TVM Capital Life Science practice as an internal start up within the firm to its market position today.